ClinicalTrials.gg
RecruitingNCT06911502Updated May 20, 2026

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

A Phase 3 interventional study of Golcadomide and Rituximab in Follicular Lymphoma, sponsored by Celgene. Recruiting at 160 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb — 2 open to participants now, 6 under way, 1 of them phase 3. Lymphoma, Follicular · Bristol-Myers Squibb.

Planned enrollment
3rd of 18
400 · median 61
Started
2025
with 2 others
Phase 3
4 of 23
1 open now
Registered
22nd of 23
by date

Among the 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb, this one is the 3rd largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2025, is one of 4 in phase 3, and was the 22nd registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

2 of the 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.

03

Conditions studied

  • Follicular Lymphoma

Keywords

  • Follicular Lymphoma
  • Second Line Follicular Lymphoma
  • Third Line Follicular Lymphoma
  • Relapsed/refractory follicular lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participant has confirmed FL (Grade 1, 2, 3a or classic FL) as assessed by local pathology. Adequate fresh tumor tissue or archived tumor biopsy from the latest relapse if available with corresponding pathology report for retrospective central pathology confirmation of relapse, is required. Evaluation from fine needle aspirate is not permitted.

- disease: i) Relapsed FL is defined as relapse after an initial response of CR or PR to the most recent prior therapy.

ii) Refractory FL is defined as best response of SD or PD or a response that lasted less than 6 months to the most recent prior therapy.

  • (ECOG) 0-2 (ECOG 3 authorized if it is due to lymphoma and not comorbidities).
  • Participant must have positron emission tomography (PET)-positive disease with at least one PET-positive lesion and on cross section imaging by CT, as defined by Lugano classification.
  • Participants with an indication for anti-lymphoma treatment as per investigator assessment based on modified Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria.
  • Participant has received at least 1 or more with one line consisting of a combination including an anti-CD20 monoclonal antibody (eg, rituximab, obinutuzumab) and an alkylating agent (eg, cyclophosphamide, bendamustine). Prior treatment with radiation therapy does not count as a line of therapy for eligibility.
  • Lab parameters:

    i) (ANC) ≥ 1,000 cells/mm3 (1.0 x 109 /L), ii) count ≥ 75,000 cells/mm3 (75 x 109 /L) iii) ≥ 7.5 g/dL

  • estimated (eGFR) ≥ 30 ml/min/1.73m².
  • Serum (AST/SGOT) or alanine transaminase (ALT/SGPT) ≤ 2.5 x (ULN). In case of documented liver involvement by lymphoma, ALT/SGPT and AST/SGOT must be ≤ 5.0× ULN.
  • Serum total ≤ 1.5 × ULN (corresponding to mild dysfunction as per National Cancer Institute Organ Dysfunction Working Group [NCI ODWG] criteria). In case of documented liver involvement by lymphoma, serum total bilirubin must be ≤ 3.0 × ULN (corresponding to moderate dysfunction as per NCI ODWG criteria). For cases of Gilberts syndrome, serum total bilirubin≤ 5.0 × ULN.
  • Adequate cardiac function for participants receiving anthracycline-based chemotherapy, defined as (LVEF) ≥ 45% as assessed by echocardiogram (ECHO) as standard of care or multi-gated acquisition scan (MUGA).

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of composite Diffuse large B-cell lymphoma (DLBCL) and FL or of transformed Non-Hodgkin Lymphoma (NHL), including history of prior large B-cell lymphomas (LBCL), or any other indolent lymphoma.
  • Follicular large cell as per 5th World Health Organization (WHO) sub-classification (grade 3b FL per WHO 4th classification) or duodenal-type FL.
  • Participant has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from compliantly participating in the study based on Investigator's judgment.
  • Participant has any condition that confounds the ability to interpret data from the study based on Investigator's or Sponsor's judgment.
  • Presence or history of central nervous system (CNS) involvement by lymphoma.
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  • Deep venous thrombosis/Pulmonary embolism within 1 month prior to enrollment.
  • Participants with a history of progressive multifocal leukoencephalopathy.
  • Participant has any other subtype of lymphoma.
  • Participant has persistent diarrhea or malabsorption ≥ Grade 2 ( v5.0), despite medical management.
  • History of another primary that has not been in remission for ≥ 3 years except for non-invasive malignancies.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Golcadomide + Rituximab

    Drug: Golcadomide · Drug: Rituximab

  • Active comparator
    Rituximab + Lenalidomide/Chemotherapy

    Rituximab + Lenalidomide or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone/prednisolone) or Rituximab + Bendamustine

    Drug: Rituximab · Drug: Lenalidomide · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone/Prednisolone · Drug: Bendamustine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) assessed by Independent Review Adjudication committee (IRAC)

    Time frame: Up to approximately 32 Months

Secondary outcomes

  1. Overall response rate (ORR) assessed by IRAC

    Time frame: Up to approximately 32 Months

  2. Overall survival (OS)

    Time frame: Up to approximately 83 Months

  3. PFS as assessed by investigator

    Time frame: Up to approximately 32 Months

  4. ORR as assessed by investigator

    Time frame: Up to approximately 32 Months

  5. Number of participants who achieve complete metabolic response (CMR)

    Time frame: Up to approximately 32 Months

  6. Duration of Response (DoR)

    Time frame: Up to approximately 32 Months

  7. Event free survival (EFS)

    Time frame: Up to approximately 32 Months

  8. Time to next anti-lymphoma treatment (TTNT)

    Time frame: Up to approximately 32 Months

  9. PFS on next anti-lymphoma treatment (PFS2)

    Time frame: Up to approximately 32 Months

  10. Time from randomization to meaningful improvement in primary domains of interest in the European Organization for Research and Treatment of Cancer - Quality of Life C30 (EORTC QLQ-C30) Questionnaire

    Time frame: Up to approximately 32 Months

  11. Time from randomization to meaningful improvement in primary domains of interest in the European Organization for Research and Treatment of Cancer - Non- Hodgkin Lymphoma- Low Grade- 20 items (EORTC QLQNHL- LG20) Questionnaire

    Time frame: Up to approximately 32 Months

  12. Minimal residual disease (MRD) negativity

    Time frame: Up to approximately 32 Months

07

Study locations

62 of 160 sites recruiting
  • Local Institution - 0225
    Birmingham, Alabama 35205, United States
    Not yet recruiting
    • Site 0225 · Contact
  • Infirmary Cancer Care
    Mobile, Alabama 36607, United States
    Recruiting
    • Furhan Yunus, Site 0014 · Contact901-634-5546
  • Alaska Oncology and Hematology
    Anchorage, Alaska 99508, United States
    Recruiting
    • Steven Liu, Site 0074 · Contact907-257-9851
  • Local Institution - 0215
    Little Rock, Arkansas 72205, United States
    Not yet recruiting
    • Site 0215 · Contact
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
    Recruiting
    • Alex Herrera, Site 0072 · Contact626-218-2405
  • UCSF Helen Diller Medical Center at Parnassus Heights
    San Francisco, California 94143, United States
    Recruiting
    • Charalambos Andreadis, Site 0119 · Contact415-238-1909
  • Local Institution - 0008
    Jacksonville, Florida 32256, United States
    Not yet recruiting
    • Site 0008 · Contact
  • Local Institution - 0214
    Tampa, Florida 33606, United States
    Not yet recruiting
    • Site 0214 · Contact
  • Local Institution - 0217
    Tampa, Florida 33612, United States
    Not yet recruiting
    • Site 0217 · Contact
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
    Marietta, Georgia 30060, United States
    Recruiting
    • Dean Kirkel, Site 0021 · Contact770-281-5100
  • Southeastern Regional Medical Center
    Newnan, Georgia 30265, United States
    Recruiting
    • Sabarish Ayyappan, Site 0245 · Contact000-000-0000
  • Local Institution - 0240
    Arlington Heights, Illinois 60005, United States
    Not yet recruiting
    • Site 0240 · Contact
  • Local Institution - 0253
    Iowa City, Iowa 52242, United States
    Not yet recruiting
    • Site 0253 · Contact
  • Local Institution - 0243
    Waukee, Iowa 50309, United States
    Not yet recruiting
    • Site 0243 · Contact
  • Local Institution - 0216
    Westwood, Kansas 66205, United States
    Not yet recruiting
    • Site 0216 · Contact
  • Local Institution - 0218
    Lexington, Kentucky 40536, United States
    Not yet recruiting
    • Site 0218 · Contact
  • Local Institution - 0023
    Baltimore, Maryland 21201, United States
    Not yet recruiting
    • Site 0023 · Contact
  • Greater Baltimore Medical Center
    Towson, Maryland 21204, United States
    Recruiting
    • Zhuoyan Li, Site 0010 · Contact443-849-3051
  • Local Institution - 0145
    Boston, Massachusetts 02114, United States
    Not yet recruiting
    • Site 0145 · Contact
  • Local Institution - 0244
    Boston, Massachusetts 02215, United States
    Not yet recruiting
    • Site 0244 · Contact
  • Local Institution - 0247
    Boston, Massachusetts 02215, United States
    Not yet recruiting
    • Site 0247 · Contact
  • Hattiesburg Clinic Hematology/Oncology
    Hattiesburg, Mississippi 39401-7233, United States
    Recruiting
    • John Hrom, Site 0013 · Contact601-261-1700
  • Local Institution - 0144
    Providence, Rhode Island 02903, United States
    Not yet recruiting
    • Site 0144 · Contact
  • Texas Oncology - Central/South Texas
    Austin, Texas 78705, United States
    Recruiting
    • Jason Melear, Site 0237 · Contact512-427-9400
  • Local Institution - 0212
    Fort Worth, Texas 76104, United States
    Not yet recruiting
    • Site 0212 · Contact
  • Local Institution - 0230
    San Antonio, Texas 78240, United States
    Not yet recruiting
    • Site 0230 · Contact
  • Texas Oncology - Northeast Texas
    Tyler, Texas 75702, United States
    Recruiting
    • Habte Yimer, Site 0236 · Contact903-579-9800
  • Local Institution - 0238
    Fairfax, Virginia 22304, United States
    Not yet recruiting
    • Site 0238 · Contact
  • Hematology Oncology Associates of Fredericksburg
    Fredericksburg, Virginia 22408, United States
    Recruiting
    • Christopher Vaughn, Site 0030 · Contact540-371-0079
  • Blue Ridge Cancer Care
    Roanoke, Virginia 24014, United States
    Recruiting
    • Amanda Gillespie-Twardy, Site 0146 · Contact540-982-0237
  • Local Institution - 0143
    Vancouver, Washington 98684, United States
    Not yet recruiting
    • Site 0143 · Contact
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Amanda Johnston, Site 0134 · Contact61288906352
  • Local Institution - 0132
    Adelaide, South Australia 5042, Australia
    Not yet recruiting
    • Site 0132 · Contact
  • Local Institution - 0131
    Hobart, Tasmania 7000, Australia
    Not yet recruiting
    • Site 0131 · Contact
  • Local Institution - 0128
    Heidelberg, Victoria 3084, Australia
    Not yet recruiting
    • Site 0128 · Contact
  • Cabrini Hospital - Malvern
    Malvern, Victoria 3144, Australia
    Recruiting
    • Adrian Minson, Site 0198 · Contact85595000
  • Local Institution - 0127
    Perth, Western Australia 6000, Australia
    Not yet recruiting
    • Site 0127 · Contact
  • Local Institution - 0224
    Perth, Western Australia 6000, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0159
    Vitória, Espírito Santo 29041-295, Brazil
    Not yet recruiting
    • Site 0159 · Contact
  • Local Institution - 0088
    Niterói, Rio de Janeiro 24220-070, Brazil
    Not yet recruiting
    • Site 0088 · Contact
  • Local Institution - 0087
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
    Not yet recruiting
    • Site 0087 · Contact
  • Local Institution - 0079
    São Paulo, São Paulo 04543-000, Brazil
    Not yet recruiting
    • Site 0079 · Contact
  • Local Institution - 0089
    Rio de Janeiro, 22250-905, Brazil
    Not yet recruiting
    • Site 0089 · Contact
  • Local Institution - 0066
    São Paulo, 01246-000, Brazil
    Not yet recruiting
    • Site 0066 · Contact
  • Local Institution - 0092
    São Paulo, 05652-900, Brazil
    Not yet recruiting
    • Site 0092 · Contact
  • Local Institution - 0200
    Victoria, British Columbia V8R 6V5, Canada
    Not yet recruiting
    • Site 0200 · Contact
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Robert Kridel, Site 0035 · Contact41694645012243
  • Local Institution - 0250
    Québec, Quebec G1J 1Z4, Canada
    Not yet recruiting
    • Site 0250 · Contact
  • Local Institution - 0192
    Sherbrooke, Quebec J1H 5N4, Canada
    Not yet recruiting
    • Site 0192 · Contact
  • Local Institution - 0226
    Sherbrooke, Quebec J1H 5N4, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0154
    Santiago, Santiago Metropolitan 7580206, Chile
    Not yet recruiting
    • Site 0154 · Contact
  • Local Institution - 0155
    Santiago, Santiago Metropolitan 8320325, Chile
    Not yet recruiting
    • Site 0155 · Contact
  • Local Institution - 0153
    Santiago, Santiago Metropolitan 8420383, Chile
    Not yet recruiting
    • Site 0153 · Contact+358 8 669 9500
  • Local Institution - 0246
    Beijing, Beijing Municipality 100038, China
    Not yet recruiting
    • Site 0246 · Contact
  • Beijing Cancer hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Yuqin Song, Site 0171 · Contact13683398726
  • Local Institution - 0172
    Fuzhou Fujian, Fujian 350001, China
    Not yet recruiting
    • Site 0172 · Contact
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Zhiming Li, Site 0173 · Contact+8613719189172
  • Local Institution - 0241
    Harbin, Heilongjiang 150081, China
    Not yet recruiting
    • Site 0241 · Contact
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Recruiting
    • Liling Zhang, Site 0176 · Contact15871725926
  • Local Institution - 0175
    Changsha, Hunan 410008, China
    Not yet recruiting
    • Site 0175 · Contact
  • Inner Mongolia Cancer Hospital
    Hohhot, Inner Mongolia 010020, China
    Recruiting
    • Ping Lingyan, Site 0235 · Contact13520201279
  • Local Institution - 0233
    Suzhou, Jiangsu 215006, China
    Not yet recruiting
    • Site 0233 · Contact
  • Local Institution - 0178
    Nanchang, Jiangxi 330006, China
    Not yet recruiting
    • Site 0178 · Contact
  • Local Institution - 0239
    Changchun, Jilin 130000, China
    Not yet recruiting
    • Site 0239 · Contact
  • Local Institution - 0177
    Changchun, Jilin 130021, China
    Not yet recruiting
    • Site 0177 · Contact
  • Local Institution - 0179
    Shenyang, Liaoning 110004, China
    Not yet recruiting
    • Site 0179 · Contact
  • Local Institution - 0242
    Shenyang, Liaoning 110042, China
    Not yet recruiting
    • Site 0242 · Contact
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Recruiting
    • Zengjun Li, Site 0180 · Contact+8613642138692
  • Local Institution - 0181
    Shanghai, Shanghai Municipality 200032, China
    Not yet recruiting
    • Site 0181 · Contact
  • Local Institution - 0249
    Shanghai, Shanghai Municipality 200065, China
    Not yet recruiting
    • Site 0249 · Contact
  • Local Institution - 0234
    Sichuan, Sichuan 646000, China
    Not yet recruiting
    • Site 0234 · Contact
  • Local Institution - 0182
    Tianjin, Tianjin Municipality 300060, China
    Not yet recruiting
    • Site 0182 · Contact
  • Tianjin People' s Hospital
    Tianjin, Tianjin Municipality 300121, China
    Recruiting
    • Xingli Zhao, Site 0227 · Contact13752255454
  • Local Institution - 0248
    Kunming, Yunnan 650118, China
    Not yet recruiting
    • Site 0248 · Contact
  • Local Institution - 0184
    Hangzhou, Zhejiang 310022, China
    Not yet recruiting
    • Site 0184 · Contact
  • Local Institution - 0174
    Zhengzhou, 450008, China
    Not yet recruiting
    • Site 0174 · Contact
  • Local Institution - 0151
    Oulu, North Ostrobothnia 90220, Finland
    Not yet recruiting
    • Site 0151 · Contact+358 8 669 9500
  • Local Institution - 0152
    Turku, Southwest Finland 20521, Finland
    Not yet recruiting
    • Site 0152 · Contact+358 2 3130000
  • Local Institution - 0150
    Helsinki, 00029, Finland
    Not yet recruiting
    • Site 0150 · Contact+358 9 4711
  • CHU Bordeaux Haut-Leveque
    Pessac, Aquitaine 33600, France
    Recruiting
    • Francois-Xavier Gros, Site 0100 · Contact33557656511
  • Local Institution - 0044
    Saint-Cloud, Hauts-de-Seine 92210, France
    Not yet recruiting
    • Site 0044 · Contact
  • Chu Saint Eloi
    Montpellier, Languedoc-Roussillon 34295, France
    Recruiting
    • Guillaume Cartron, Site 0047 · Contact+33675926918
  • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
    Nantes, Loire-Atlantique 44093 Cedex 1, France
    Recruiting
    • Thomas Gastinne, Site 0120 · Contact33240083271
  • Hopital Claude Huriez - CHU de Lille
    Lille, Nord 59037, France
    Recruiting
    • Franck Morschhauser, Site 0048 · Contact33320445713
  • Local Institution - 0042
    Pierre-Bénite, Rhône 69310, France
    Not yet recruiting
    • Site 0042 · Contact
  • Local Institution - 0191
    Paris, 75010, France
    Not yet recruiting
    • Site 0191 · Contact
  • Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE
    Toulouse, 31100, France
    Recruiting
    • Loïc Ysebaert, Site 0121 · Contact33531156351
  • Local Institution - 0163
    Ulm, Baden-Wurttemberg 89081, Germany
    Not yet recruiting
    • Site 0163 · Contact
  • Klinikum Augsburg
    Augsburg, Bavaria 86156, Germany
    Recruiting
    • Rainer Claus, Site 0161 · Contact+491791098382
  • Local Institution - 0220
    Göttingen, Lower Saxony 37075, Germany
    Not yet recruiting
    • Site 0220 · Contact
  • GEFOS Gesellschaft f. onkologische Studien
    Dortmund, North Rhine-Westphalia 44263, Germany
    Recruiting
    • Sandra Ketzler-Henkel, Site 0166 · Contact02312069011
  • Local Institution - 0193
    Düsseldorf, North Rhine-Westphalia 40225, Germany
    Not yet recruiting
    • Site 0193 · Contact
  • Local Institution - 0231
    Münster, North Rhine-Westphalia 48153, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0232
    Münster, North Rhine-Westphalia 48153, Germany
    Not yet recruiting
    • Site 0232 · Contact
  • Universitaetsklinikum des Saarlandes
    Homburg, Saarland 66424, Germany
    Recruiting
    • Konstantinos Christofyllakis, Site 0164 · Contact+68411615358
  • HELIOS Klinikum Erfurt
    Erfurt, Thuringia 99089, Germany
    Recruiting
    • Sebastian Scholl, Site 0222 · Contact+493617812476
  • Universitätsklinikum Jena
    Jena, Thuringia 07747, Germany
    Recruiting
    • Ulf Schnetzke, Site 0167 · Contact036419327113
  • Klinikum Chemnitz Ggmbh
    Chemnitz, 09116, Germany
    Recruiting
    • Mathias Haenel, Site 0165 · Contact4937133344500
  • Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf
    Dresden, 01307, Germany
    Recruiting
    • Thomas Illmer, Site 0187 · Contact00493514400022
  • Local Institution - 0162
    München, 81337, Germany
    Not yet recruiting
    • Site 0162 · Contact

Showing the first 100 of 160 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2028, 32 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's planned 32 months is below that.

Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 4, 2025
StartActual
Jul 28, 2025
Primary completionEst.
Apr 24, 2028
CompletionEst.
Jul 31, 2030
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06911502
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Jul 28, 2025
Primary completion
Apr 24, 2028 (estimated)
Completion
Jul 31, 2030 (estimated)
Last update
May 20, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
8559073286
First line of the email MUST contain the NCT# and Site #.
Contact
Bristol Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golcadomide

Start the discussion